Remarkably, the blood–brain permeable RSK inhibitor BI-D1870 prevented audiogenic seizures in Fmr1 knock-out mice, suggesting a potential drug candidate for FXS treatment [77]. This evidence concerns the gene RPS6KA3 and fragile X syndrome.